Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ISPAGHULA HUSKS
Madaus GmbH
65/2.2 %w/ %w/w
Granules
2007-11-30
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA1288/003/001 Case No: 2042926 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to Transferred from PA0375/002/001. MADAUS GMBH 51101 COLOGNE, GERMANY an authorisation, subject to the provisions of the said Regulations, in respect of the product COLOFIBRE GRANULES The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 30/11/2007 until 05/12/2008. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 01/12/2007_ _CRN 2042926_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colofibre Granules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For excipients, see 6.1. 3 PHARMACEUTICAL FORM Granules Fine-grained, yellow-brown granules with an aromatic odour. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of patients requiring a high fibre diet regimen and as a bulk forming agent in the regulation of bowel function. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral administration. Colofibre Granules should be placed dry on the tongue and without chewing or crushing swallowed with a glass of water or warm drink. Colofibre Granules can be taken mixed just before consumption with yoghurt, Read the complete document